NEW YORK (GenomeWeb) –PerkinElmer Genomics has chosen BioDiscovery's NxClinical software for genomic data analysis for its services, BioDiscovery announced today.
The software will enable PerkinElmer Genomics to provide fast and accurate copy number variation insights from whole-genome sequencing, whole-exome sequencing, and targeted panels, El Segundo, California-based BioDiscovery said. The product integrates copy number data, sequence variants, and allelic changes obtained from microarray and next-generation sequencing technologies while allowing combined analysis and interpretation of genomic variants on a single, platform-agnostic system.
"As a leader in genetic and genomic testing, PerkinElmer needs data analysis solutions that offer integrated, comprehensive, and unique capabilities such as analyzing NGS data to make CNV calls," BioDiscovery President Soheil Shams said in a statement. "NxClinical incorporates multiple technologies and platforms and allows interpretation of genomic variants of any size from single nucleotide to large copy number changes."
Madhuri Hedge, VP and CSO of PerkinElmer Genomics, also noted that the company has now integrated NxClinical into its pipeline for the CNGnome test for detecting large copy number changes throughout the genome, "and are pleased with the results and the efficiency of the entire workflow."
BioDiscovery added that its software tools are meant to assist clinical researchers and are not intended for primary diagnosis.
Financial terms of the deal were not disclosed.